Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526733 · ClinicalTrials.gov registry record · Phase 4
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
A Phase 4 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT01526733 is a Phase 4 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT01526733, a Phase 4 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex® (recombinant human hyaluronidase PH20 \[rHuPH20\]) injection at the time of infusion set insertion compared to sham injection.
Interventions
- DRUG Insulin aspart
- DRUG Sham Injection
- DRUG Insulin lispro
- DRUG Recombinant human hyaluronidase PH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526733
The ClinicalTrials.gov registry entry for NCT01526733 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Insulin aspart is the first listed.
NCT01526733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526733 about?
NCT01526733 is a clinical study titled "Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase". The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex® (recombinant human hyaluronidase PH20 \[rHuPH20\]) injection at the time of infusi...
What is the current status of trial NCT01526733?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2011-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01526733?
The interventions under investigation include: Insulin aspart (DRUG), Sham Injection (DRUG), Insulin lispro (DRUG), Recombinant human hyaluronidase PH20 (DRUG).
Who is sponsoring clinical trial NCT01526733?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.